Novo Nordisk A/S (NYSE:NVO) Stock Sold Off by Rep. Kevin Hern

Key Points

• Rep. Kevin Hern sold Novo Nordisk shares worth between $1,001 and $15,000 from his traditional IRA on August 31, according to a congressional filing.
• Novo Nordisk shares opened at $38.69, near the bottom of their 52-week range of $35.12 to $64.16. Analysts have a consensus “Hold” rating and an average price target of $64.94.
• The company faces intensifying obesity-drug competition, although its CagriSema trial results, a potential €1.165 billion delivery-technology deal and a DKK 15 billion buyback program provide possible support for its turnaround.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on August 31st. The trade occurred in the Representative's "KEVIN HERN TRADITIONAL IRA" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of CenterPoint Energy NYSE: CNP on 9/15/2026.
• Sold $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of STERIS NYSE: STE on 9/15/2026.
• Sold $1,001 - $15,000 in shares of Seagate Technology NASDAQ: STX on 9/15/2026.
• Sold $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 9/14/2026.
• Sold $15,001 - $50,000 in shares of IQVIA NYSE: IQV on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 9/14/2026.
• Sold $15,001 - $50,000 in shares of Emerson Electric NYSE: EMR on 9/14/2026.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $38.69 on Tuesday. The stock has a market capitalization of $172.77 billion, a price-to-earnings ratio of 9.46, a PEG ratio of 1.27 and a beta of 0.74. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The business's fifty day moving average price is $45.51 and its 200-day moving average price is $43.87.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. On average, equities analysts predict that Novo Nordisk A/S will post 3.54 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. This is a negative change from Novo Nordisk A/S's previous dividend of $1.2751. Novo Nordisk A/S's payout ratio is currently 20.05%.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent research reports. Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, August 5th. Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating in a report on Thursday, August 27th. Nordea Equity Research raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Friday, June 19th. Finally, BMO Capital Markets reiterated a "market perform" rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $64.94.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema produced a meaningful clinical win. In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes receiving the 1 mg/1 mg dose lost an estimated 12.4% of body weight after 60 weeks, giving Novo a result that compares favorably with Eli Lilly’s tirzepatide and potentially strengthens the company’s comeback prospects. Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?
• Positive Sentiment: Novo is expanding its delivery-technology capabilities. The company agreed to license Nanexa’s PharmaShell technology in a deal worth up to €1.165 billion, potentially supporting longer-acting drug formulations and strengthening its future obesity and diabetes pipeline. Novo Nordisk Licenses Nanexa's PharmaShell In Deal Worth Up To EUR 1.165 Bln
• Positive Sentiment: Share repurchases provide support. Novo continues a buyback program of up to DKK 15 billion over 12 months, which could help support per-share value and signal management’s confidence in the depressed valuation. Novo Nordisk A/S - share repurchase programme
• Neutral Sentiment: Citi maintained a DKK 310 price target while the shares traded near DKK 253, indicating substantial potential upside but no change in the bank’s current view. Novo Nordisk stock trades at DKK 253.00 as Citi keeps target at DKK 310.00
• Negative Sentiment: Competition is broadening. Roche reported mid-stage data showing its experimental enicepatide improved blood sugar control and delivered 15.5% average weight loss, adding another potential rival to Novo’s obesity portfolio. Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
• Negative Sentiment: Investors remain concerned that Eli Lilly is tightening its grip on the U.S. GLP-1 market and that Novo has yet to demonstrate a convincing “second act” beyond its flagship weight-loss franchise. CFRA’s bearish stance reinforces those concerns.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership purchased a new stake in Novo Nordisk A/S in the 1st quarter worth $287,660,000. Maverick Capital Ltd. purchased a new position in shares of Novo Nordisk A/S during the first quarter valued at about $76,444,000. Contrarius Group Holdings Ltd bought a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $47,337,000. Public Employees Retirement System of Ohio bought a new stake in shares of Novo Nordisk A/S in the first quarter worth about $27,802,000. Finally, Franklin Resources Inc. lifted its position in shares of Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company's stock worth $748,064,000 after buying an additional 717,719 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.